Guardant Health Dives After Losing A Patent Dispute; Judge Orders Royalties

Guardant Health (GH) stock tumbled Monday after losing a patent battle against privately held TwinStrand Biosciences and the University of Washington. The judge ordered Guardant to pay more than $245.2 million in damages, accrued royalty and interest. Guardant will also have to pay a 6% royalty on sales of key products, including its Guardant360 and Shield tests.